CINV

Palonosetron Noninferior to Ondansetron for Pediatric Chemotherapy-induced Vomiting

Palonosetron Noninferior to Ondansetron for Pediatric Chemotherapy-induced Vomiting

By

In a prospective study, researchers sought to determine the noninferiority of palonosetron to ondansetron in pediatric patients with cancer receiving moderate or high emetogenic chemotherapy.

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV

By

FDA issues black box warning for rolapitant regarding the potential for anaphylaxis, anaphylactic shock, and other hypersensitivity reactions in patients receiving the injectable emulsion for CINV prophylaxis.

Fosaprepitant Improves Standard Antiemetic Therapy in Pediatric Patients

Fosaprepitant Improves Standard Antiemetic Therapy in Pediatric Patients

By

Data presented at ASH 2017 illustrates the effectiveness of 2 prophylactic antiemetic regimens in pediatric patients receiving moderately or highly emetogenic chemotherapy.

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

By

A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.

Aprepitant Plus Standard Antiemetic Regimen Prevents CINV With FOLFOX for CRC

Aprepitant Plus Standard Antiemetic Regimen Prevents CINV With FOLFOX for CRC

By

A small study of 50 patients undergoing FOLFOX for CRC determined if adding aprepitant to standard antiemetic prophylactic treatment would improve CINV in this patient population.

Netupitant Plus Palonosetron Safe, Effective Strategy for CINV in Lung Cancer

Netupitant Plus Palonosetron Safe, Effective Strategy for CINV in Lung Cancer

By

A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.

Fosaprepitant for CINV Prevention Dose Proportional in Older Pediatric Patients

Fosaprepitant for CINV Prevention Dose Proportional in Older Pediatric Patients

By

Fosaprepitant is used to prevent CINV in adult patients, and this phase 2b dose-ranging study of pediatric patients aged newborn to 17 years determined the appropriate doses for younger patients.

Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer

Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer

By

A randomized study was conducted to determine the efficacy of prophylactic prochlorperazine in reducing opioid-induced nausea and vomiting in patients with cancer receiving opioids for pain management.

Adding Thalidomide to Palonosetron, Dexamethasone Reduces CINV

Adding Thalidomide to Palonosetron, Dexamethasone Reduces CINV

By

Delayed CINV was improved significantly in patients receiving highly emetogenic chemotherapy for cancer when thalidomide was added to palonosetron and dexamethasone regimen.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs